Serum alpha-fetoprotein is the standard clinical biomarker for hepatocellular carcinoma. However, a new study from experts at the Cleveland Clinic shows that other emerging biomarkers, such as ...

Background: AFP response, defined as a decrease in serum levels of the tumor marker AFP after therapy, may be associated with improved survival of patients (pts) with HCC treated with locoregional or ...

The C-reactive protein and alpha-fetoprotein in immunotherapy score identified patients with favorable hepatocellular carcinoma disease control and survival, according to a study presented at the ...

Alpha-fetoprotein (AFP) is considered to be an indicator of tumor activity in hepatocellular carcinoma (HCC). We present a novel correlation of AFP response to radiologic response, time-to-progression ...

If the HCC prevalence rates were more like those seen in most liver clinics, ~5%, the positive predictive value (PPV) of an AFP of 20 ng/mL would be only 41.5%, and even at a cutoff of 400 ng/mL ...

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies globally and is the third leading cause of ...

Among patients with screen-detected HCC, nearly half were identified through imaging studies alone (44.6%) or by both imaging and AFP tests (44.7%). The remaining 10.6% had HCC identified solely ...

REACH-2 was a randomized, double-blind, placebo-controlled trial that enrolled 292 patients with hepatocellular carcinoma (HCC) who were intolerant to, or had disease progression while on or ...

In a new study, alpha-fetoprotein measurement in combination with ultrasound improved surveillance effectiveness in patients with cirrhosis, according to published data in The American Journal of ...

Over a median follow-up of five years, patients with MASLD had an approximately two-fold higher risk of developing hepatocellular carcinoma (HCC) compared to those without MASLD, after adjusting ...